Table 1.
Clinical characteristics according to their pathologic diagnosis
| Pathologic diagnosis | No. cases | Male/female ratio | Median age, y (range) | Median transformed (large) T cells, % (range)* | TCR-γ gene rearrangement by PCR |
|---|---|---|---|---|---|
| AITL | 36 | 1.8 | 65 (43-87) | 30 (12-59) | 3/3 |
| ALK+ ALCL | 20 | 1.0 | 27 (12-43) | 90 (50-95) | 5/8 |
| ALK − ALCL | 8 | 3.0 | 64 (45-86) | 89 (85-94) | 2/4 |
| ATLL | 12 | 5.0 | 60 (47-80) | 45 (17-80) | ND |
| T/NKCL | 14 | 0.70 | 33 (28-72) | NA | NA |
| PTCL-NOS | 44 | 2.1 | 65 (18-65) | 58 (7-94) | 9/10 |
Not included in this analysis are other 10 cases of PTCL rare entities, including hepatosplenic T-cell lymphoma, mycosis fungoides, enteropathy-associated T-cell lymphoma, and T-cell prolymphocytic leukemia.
AITL indicates angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large-cell lymphoma; ALK, anaplastic lymphoma kinase; ATLL, adult T-cell leukemia/lymphoma; NA, not available; ND, not determined; PCR, polymerase chain reaction; PTCL-NOS, peripheral T-cell lymphoma–not otherwise specified; TCR-γ, T-cell receptor-γ; and T/NKCL, T-/natural killer-cell lymphomas.
*
Average calculated from 4 pathologists.